Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Veronika Schirmer"'
Autor:
Ute Kreibich, Antje Haas, Hartmut Goldschmidt, Wolfram Pönisch, Thomas Boldt, Robert Rohrberg, Dietger Niederwieser, Andreas Schwarzer, Franz Albert Hoffmann, Elke Schwalbe, Thomas Zehrfeld, Jens Uhlig, Marta Rozanski, Ute Ritter, Veronika Schirmer
Publikováno v:
British Journal of Haematology. 143:191-200
Thalidomide is an effective agent for advanced refractory or relapsed multiple myeloma (MM), although dose-limiting toxicity (DLT) may limit its use. This Phase I study found that a combination of low-dose thalidomide with bendamustine and prednisolo
Autor:
K. Bremer, P. Richter, Andreas Schwarzer, Chr. Müller, Rita Pasold, Manfred Schulze, Dietger Niederwieser, Chr. Klinkenstein, Klaus Dachselt, J. Weniger, C. Boewer, H. Arzberger, Mathias Freund, Antje Schulze, Cornelia Winkelmann, C. A. Müller, Veronika Schirmer, B. Ismer, Hans-Joerg Fricke, A. Franke, S. Hahnfeld, Michael Herold
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 132:105-112
Purpose: The purpose of this study was to compare the efficacy and toxicity of bendamustine, vincristine + prednisone (BOP) with a standard regimen of cyclophosphamide, vincristine + prednisone (COP) in patients with previously untreated advanced ind
Autor:
A. Bittrich, Antje Schulze, B. Harksel, Michael Assmann, Norbert Grobe, Mathias Freund, G. Wilhelm, P. Richter, E. Stelzer, K. Merkle, Th. Friedrich, Dietger Niederwieser, R. Šubert, Rita Pasold, Manfred Schulze, W. Helbig, Michael Herold, Klaus Dachselt, Paris S. Mitrou, Veronika Schirmer, Wolfram Pönisch
Publikováno v:
Journal of cancer research and clinical oncology. 132(4)
Purpose: This randomized phase III study compared bendamustine and prednisone (BP) to standard melphalan and prednisone (MP) treatment in previously untreated patients with multiple Myeloma (MM). Patients and Methods: To be included, patients had to
Autor:
Cornelia Becker, Ute Kreibich, Christian Junghanß, Rainer Krahl, Erika Kettner, Mathias Haenel, Hans-Heinrich Wolf, Thomas Ittel, Antje Schulze, Dietrich Kaempfe, Renate Huhn, Georg Maschmeyer, W. Helbig, Axel Florschuetz, Bernd Opitz, Dietger Niederwieser, Michael Assmann, Ulrich Wedding, Dirk Hasenclever, Ernst Zschuppe, Veronika Schirmer, Astrid Franke, Wolfram Poenisch, Mathias Schulze, Norbert Grobe, Norma Peter, Johannes G. Meran, Detlev Haehling, Gottfried Doelken
Publikováno v:
Blood. 112:2966-2966
Clinical trials on different cytarabine doses for treatment of AML provide evidence of a dose response effect, but also for increase toxicity after high dose AraC (HDAC). Pharmacokinetic measurements of cytarabine-triphosphate (AraC-CTP), which is th
Autor:
Ulrich Wedding, Cornelia Becker, Ute Kreibich, Dietger Niederwieser, Hans-Heinrich Wolf, Rainer Krahl, M. Freund, Renate Huhn, Antje Schulze, Norma Peter, H. K. Al-Ali, Ernst Zschuppe, Karin Senftleben, F. Fiedler, Michael Cross, Manfred Schulze, Thomas Ittel, Veronika Schirmer, Lutz Uharek, Bernd Opitz, A. Gerhardt, Erika Kettner, Axel Florschuetz, Norbert Grobe, Michael Assmann, Gottfried Dölken, Astrid Franke, Simone Heyn, W. Helbig, Thoralf Lange, Detleff Haehling
Publikováno v:
Blood. 108:264-264
Cytogenetic high risk AML (abn 3q26, abn 11q23, −5/5q-, −7/7q- and complex) has a dismal prognosis with a two year overall survival (OS) below 20% even in young patients. Attempts to improve survival by intensifying consolidation chemotherapy hav
Autor:
A. Gerhardt, Astrid Franke, Cornelia Becker, Michael Assmann, W. Helbig, Norbert Grobe, Ute Kreibich, Mathias Freund, Simone Heyn, Dietger Niederwieser, F. Fiedler, Gottfried Doelken, Thoralf Lange, Erika Kettner, Klaus Fenchel, Kristiane Senftleben, Antje Schulze, Axel Florschuetz, Thomas Ittel, Rainer Krahl, Bernhard Opitz, Wolfram Poenisch, Hans-Heinrich Wolf, Detlev Haehling, Michael Cross, Manfred Schulze, Ullrich Wedding, L Uharek, Norma Peter, Renate Huhn, Veronika Schirmer, Haifa Al Ali, Ernst Zschuppe, Niklas Zojer
Publikováno v:
Blood. 108:1921-1921
AML patients with unfavourable cytogenetics generally have a poor outcome. Over the last decade a number of strategies to improving survival have been assessed by the East German Study Group (OSHO). Here, we analyse the results of three protocols (AM
Autor:
Wolfram Poenisch, Robert Rohrberg, Veronika Schirmer, Marta Rozanski, Ute Kreibich, Ute Ruffert, Hartmut Goldschmidt, Thomas Boldt, Elke Schwalbe, Andreas Schwarzer, Franz-Albert Hoffmann, Dietger Niederwieser, Thomas Zehrfeld, Jens Uhlig, Antje Haas
Publikováno v:
Blood. 108:3564-3564
Thalidomide is an active single agent in advanced relapsed or refractory multiple myeloma (MM). The combination of low dose thalidomide with bendamustine and prednisolone might maintain or increase efficacy of the drug while avoiding dose limiting to
Autor:
Heiner Wolf, Bernhard Opitz, Christian Klinkenstein, Mathias Freund, Johannes G. Meran, Rainer Krahl, Michael Assmann, Cornelia Becker, Rita Subert, Klaus Dachselt, Astrid Franke, Ute Hegenbart, W. U. Knauf, Renate Huhn, Wolfram Poenisch, Cornelia Winkelmann, Norma Peter, Veronika Schirmer, Haifa Al Ali, Ute Kreibich, Luisa Mantovani, Ernst Zschuppe, Ulrich Wedding, F. Fiedler, Michael Herold, Rita Pasold, Manfred Schulze, Dietger Niederwieser, Ursula Haak, W. Helbig, Thomas Ittel, Erika Kettner, Dirk Hasenclever, Norbert Grobe
Publikováno v:
Blood. 106:1851-1851
Outcome of elderly patients with AML is usually poor. Increased incidence of high risk AML and intolerance against dose escalation are the main causes for treatment failure. Pharmacokinetic measurements indicated that intracellular Ara-CTP formation
Autor:
Ute Kreibich, Dietger Niederwieser, Cornelia Becker, Wolfram Poenisch, Thomas Ittel, Ursula Haak, Wolfgang Knauf, Rainer Krahl, Michael Assmann, W. Helbig, Dietrich Kaempfe, Johannes Meran, Norma Peter, Cornelia Winkelmann, Rita Pasold, Manfred Schulze, Erika Kettner, Ferdinand Fiedler, Norbert Grobe, Wolfgang Schultze, Juergen Steglich, Hans Heinrich Wolf, Ulrich Wedding, Veronika Schirmer, Haifa Al Ali, M. Freund, Bernhard Opitz, Manfred Herold, Rita Subert, Klaus Dachselt, Renate Huhn, Christian Klinkenstein
Publikováno v:
Blood. 104:880-880
Treatment of elderly patients (pts) with AML requires a sensitive balance between efficacy and toxicity. In the AML97 study all pts with AML > 60 years (y) were registered and, according to their clinical status, treated in curative, palliative or su